NASDAQ:HEPA

Hepion Pharmaceuticals Stock News

etoro logo Buy HEPA
*Your capital is at risk
$0.0600
-0.0030 (-4.76%)
At Close: Jun 03, 2026
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X Genomics Inc (NASDAQ:...
Oct 07, 2020 (The Expresswire) -- Global “Nash Drugs Market” research report offers qualitative and quantitative insights in relation to industry growth...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 1) 10X Genomics Inc (NASDAQ:...
GENFIT SA (NASDAQ:GNFT) Q2 2020 Results Conference Call September 30, 2020 04:30 PM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - CEO Dean Hum - Chief Scien
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, in
Can-Fite Selected to Deliver Late-Breaking Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases
COVID-19 forces one of the biggest surges in tech investment in history, finds Harvey Nash/KPMG CIO Survey.
In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two d
EDISON, NJ / ACCESSWIRE / September 17, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a biopharmaceutical company focused on the development of therapeutic drugs for the treat
Trésorerie et équivalents de trésorerie à 52,3 M€ au 30 juin 2020 Succès de l'introduction en bourse sur le Nasdaq Global Market, avec une levée de 107,7 M$ (94,9 M€) prolongeant la vis
Trésorerie et équivalents de trésorerie à 52,3 M€ au 30 juin 2020Succès de l'introduction en bourse sur le Nasdaq Global Market, avec une levée de 107,7...
Regulatory News: POXEL SA (Paris:POXEL) (Euronext : POXEL — FR0012432516), société biopharmaceutique spécialisée dans le développement de traitements
Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for NASH
Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE